REFERENCES
1. Shetty AV, Wong DJ. Systemic treatment for squamous cell carcinoma of the head and neck. Otolaryngol Clin North Am. 2017;50:775-82.
2. Goel B, Tiwari AK, Pandey RK, et al. Therapeutic approaches for the treatment of head and neck squamous cell carcinoma - an update on clinical trials. Transl Oncol. 2022;21:101426.
3. Li Y, Yang C, Gan Y, Lu F, Qin Y. Radiotherapy plus cetuximab or cisplatin in head and neck squamous cell carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Eur Arch Otorhinolaryngol. 2023;280:11-22.
4. Griso AB, Acero-Riaguas L, Castelo B, Cebrián-Carretero JL, Sastre-Perona A. Mechanisms of cisplatin resistance in HPV negative head and neck squamous cell carcinomas. Cells. 2022;11:561.
5. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007;63:12-31.
6. Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27-36.
7. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat. 2011;14:22-34.
9. Ma X, Huang J, Du W, et al. ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: a meta-analysis. Oral Oncol. 2015;51:483-92.
10. Ciaparrone M, Caspiani O, Bicciolo G, et al. Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncology. 2015;89:227-34.
11. Köberle B, Ditz C, Kausch I, Wollenberg B, Ferris RL, Albers AE. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo. Int J Oncol. 2010;36:1277-84.
12. Vaezi A, Wang X, Buch S, et al. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2011;17:5513-22.
13. Burkitt K, Ljungman M. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines. Cancer Lett. 2007;253:131-7.
14. Su WP, Ho YC, Wu CK, et al. Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways. Sci Rep. 2017;7:3879.
15. Gadhikar MA, Sciuto MR, Alves MV, et al. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther. 2013;12:1860-73.
16. Robinson AM, Rathore R, Redlich NJ, et al. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma. Cell Death Dis. 2019;10:867.
17. Chaudhary RK, Khanal P, Mateti UV, Shastry CS, Shetty J. Identification of hub genes involved in cisplatin resistance in head and neck cancer. J Genet Eng Biotechnol. 2023;21:9.
18. Theile D, Ketabi-Kiyanvash N, Herold-Mende C, et al. Evaluation of drug transporters’ significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011;33:959-68.
19. Peters T, Lindenmaier H, Haefeli WE, Weiss J. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:291-9.
20. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Bioanalytical method validation: guidance for industry. 2018. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. [Last accessed on 4 Sep 2025].
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25:402-8.
22. Sikder RK, Ellithi M, Uzzo RN, et al. Differential effects of clinically relevant N- versus C-terminal truncating CDKN1A mutations on cisplatin sensitivity in bladder cancer. Mol Cancer Res. 2021;19:403-13.
23. Koster R, di Pietro A, Timmer-Bosscha H, et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest. 2010;120:3594-605.
24. Zhan Z, Luo X, Shi J, Chen L, Ye M, Jin X. Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors and potential therapeutic agents (Review). Exp Ther Med. 2025;29:82.
25. Zamagni A, Pasini A, Pirini F, et al. CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells. Int J Oncol. 2020;56:1574-84.
26. Chaisaingmongkol J, Popanda O, Warta R, et al. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma. Oncogene. 2012;31:5108-16.
27. Zhang L, Chang J, Wu X. Expression analysis of FANCD2 in endometrial carcinoma. Cancer Manag Res. 2024;16:1715-25.
28. Wu CK, Shiu JL, Wu CL, et al. APLF facilitates interstrand DNA crosslink repair and replication fork protection to confer cisplatin resistance. Nucleic Acids Res. 2024;52:5676-97.
29. Xie X, Zhao Y, Du F, et al. Pan-cancer analysis of the tumorigenic role of Fanconi anemia complementation group D2 (FANCD2) in human tumors. Genomics. 2024;116:110762.
30. Chen YF, Pang YC, Wang HC, et al. Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non-small cell lung cancer. Br J Pharmacol. 2024;181:1221-37.
31. Dai CH, Li J, Chen P, Jiang HG, Wu M, Chen YC. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells. J Biomed Sci. 2015;22:77.
32. Chirnomas D, Taniguchi T, de la Vega M, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006;5:952-61.
33. Andersson A, Fagerberg J, Lewensohn R, Ehrsson H. Pharmacokinetics of cisplatin and its monohydrated complex in humans. J Pharm Sci. 1996;85:824-7.
34. Martens-de Kemp SR, Dalm SU, Wijnolts FM, et al. DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. PLoS One. 2013;8:e61555.
35. Mezencev R. Interactions of cisplatin with non-DNA targets and their influence on anticancer activity and drug toxicity: the complex world of the platinum complex. Curr Cancer Drug Targets. 2015;14:794-816.
36. Mondal P, Meeran SM. Emerging role of non-coding RNAs in resistance to platinum-based anti-cancer agents in lung cancer. Front Pharmacol. 2023;14:1105484.
37. Deng Z, Chen S, Liu G, Zhu G. Unlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance. RSC Chem Biol. 2023;4:1003-13.
38. Ferraro G, Sanfilippo V, Chiaverini L, et al. Cisplatin binding to angiogenin protein: new molecular pathways and targets for the drug’s anticancer activity. Dalton Trans. 2023;52:9058-67.
39. Stornetta A, Zimmermann M, Cimino GD, Henderson PT, Sturla SJ. DNA adducts from anticancer drugs as candidate predictive markers for precision medicine. Chem Res Toxicol. 2017;30:388-409.
40. Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest. 1991;87:772-7.
